The Lancet Gastroenterology & Hepatology in conversation with
Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgical management of malignant bowel obstruction, and more.
Episodes
82 episodes
Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis
Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.Read the full article:
•
14:42
Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease
Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and ...
•
34:15
Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer
Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therap...
•
18:23
Nancy Baxter on the duration of colorectal cancer risk reduction with a complete colonoscopy
Nancy Baxter (University of Melbourne) discusses a population-based study on the duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy.Read the full article:
•
25:05
Sanna Nybacka and Magnus Simrén on a trial of low FODMAP diets versus low carbohydrate diets in IBS
Sanna Nybacka and Magnus Simrén (University of Gothenburg) discuss the CARIBS randomised controlled trial of a low FODMAP diet versus a low-carbohydrate diet versus pharmacological treatment in IBS.Read the full article:
•
23:16
Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease
Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease.Read the full article:
•
19:55
Yusuke Shimakawa on a simple score for hepatitis B treatment eligibility in Africa
Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa.Read the full article:
•
20:54
Mads Israelsen on validating the new steatotic liver disease nomenclature in people with excessive alcohol intake
Mads Israelsen (Odense University Hospital) discusses a study to validate the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake.Read the full article:
•
16:39
Louise Dye on the role of expectancy and gluten in non-coeliac gluten sensitivity
Louise Dye (University of Leeds) discusses a trial exploring the role of expectancy and gluten ingestion on symptoms in people with non-coeliac gluten sensitivity.Read the full article:
•
23:19
Tzu-Chan Hong on the primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region
Tzu-Chan Hong (National Taiwan University Cancer Centre) discusses a systematic review and meta-analysis on primary antibiotic resistance of Helicobacter pylori between 1990 and 2022 in the Asia-Pacific region.Read the full article:...
•
14:40
Sarah Moen on metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after colectomy
Sarah Moen (Erasmus University Medical Center) discusses a retrospective cohort study examining the risk of metachronous colorectal cancer after partial or extensive colectomy in carriers of different pathogenic Lynch syndrome variants....
•
14:45
Anna Emilie Kann on the causes of mortality in patients with alcohol-related liver disease
Anna Emilie Kann (Zealand University Hospital, Denmark) discusses a population-based study done in Denmark exploring the causes of mortality in patients with alcohol-related liver disease.Read the full article:
•
16:19
Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction
Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction.Read the full article:
•
16:31
Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis
Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eo...
•
14:29
Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease
Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease.Read the full article:
•
17:41
Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis
Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortal...
•
12:48
Adelina Artenie on the incidence of HIV and HCV in people who inject drugs
Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender. Read the full article:
•
17:15
Johan Burisch on the costs of inflammatory bowel disease in high-income settings
Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings.Rea...
•
20:00
Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease
Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.Read the full article:
•
21:30
Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer
Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma. Read t...
•
20:20
Dan Turner on vedolizumab in children with IBD
Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD.Read the full article:
•
14:51
Simon Baunwall on faecal microbiota transplantation for first or second Clostridioides difficile infection
Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection.Read the full article:
•
15:21
James Alexander on immune responses to COVID-19 vaccination in patients with IBD
James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease.Read the full...
•
13:48
Filip Knop on liraglutide for bile acid diarrhoea
Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea.Read the full article:
•
15:02
Edward Kim on radiation segmentectomy for unresectable very early to early stage hepatocellular carcinoma
Edward Kim (Icahn School of Medicine at Mount Sinai) discusses the single-arm RASER study of radiation segmentectomy for patients with unresectable very early to early stage hepatocellular carcinoma.Read the full article:
•
14:06